As an emerging effective anti-tumor therapy approach, immunotherapy represented mainly by the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway has shown great therapeutic potential in many tumor types (4, 5). This evidence concerns the gene CD274 and neoplasm.